Cost-Effectiveness Analysis of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for Patients With High-Risk Early Stage Triple-Negative Breast Cancer in Chile

Author(s)

Daniela Lahoz, MSc1, Carlos Balmaceda, MPhil, MSc2.
1Epsilon Research, Santiago, Chile, 2Bocconi University, Milano, Italy.
OBJECTIVES: To evaluate the cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab, versus standard chemotherapy, in high-risk, early-stage triple-negative breast cancer from the perspective of the Chilean public health-care system.
METHODS: A four-state semi-Markov cohort model (event-free, locoregional recurrence, metastatic recurrence and death) was constructed with a 45-year time horizon and a 3 % annual discount rate. Transition probabilities were drawn from KEYNOTE-522; costs (2025 Chilean pesos, CLP) from CENABAST and the 2021 Cost Verification Study; utilities from the EQ-5D data in KEYNOTE-522. Deterministic sensitivity analysis and 10,000 Monte-Carlo simulations were undertaken to propagate second-order uncertainty. The cost-effectiveness threshold was set at one gross domestic product per capita (CLP 16.4 million per quality-adjusted life-year [QALY]).
RESULTS: Pembrolizumab yielded 18.58 QALYs at a cost of CLP 102.8 million, compared with 15.97 QALYs and CLP 27.0 million for chemotherapy; the 2.61-QALY gain required an additional CLP 75.8 million (incremental cost-effectiveness ratio [ICER] = CLP 29.0 million/QALY). Tornado analysis identified the pembrolizumab price, neoadjuvant cost and event-free utility as key drivers; a 10 % reduction in the drug’s price was sufficient to change the decision. The cost-effectiveness acceptability curve indicated a 0 % probability of cost-effectiveness at one GDPpc and 100 % above CLP 50 million/QALY (>3 GDPpc).
CONCLUSIONS: At the threshold of one GDPpc, the peri-operative pembrolizumab strategy is not efficient: each additional QALY costs roughly twice the willingness-to-pay ceiling, implying a substantial opportunity cost relative to higher-value interventions within the public system. Only marked price concessions, risk-sharing agreements or the adoption of more permissive thresholds could render the regimen cost-effective without compromising overall health maximisation.

Conference/Value in Health Info

2025-11, ISPOR Europe 2025, Glasgow, Scotland

Value in Health, Volume 28, Issue S2

Code

EE212

Topic

Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Value of Information

Disease

Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×